Long COVID Trial Finds No Added Benefit from Pro-Resolving Supplement Over Placebo

Millions of people worldwide continue to live with post-COVID-19 condition, a stubborn constellation of symptoms that persists long after the acute infection has cleared. Fatigue and breathlessness rank among the most disabling of these complaints, robbing many patients of the ability to work, exercise, or simply get through a normal day. Against this backdrop, a team of Spanish researchers has reported the results of ARACOV-02, a rigorously designed randomized controlled trial that tested whether a nutritional supplement enriched with specialized pro-resolving mediators could amplify the benefits of a structured rehabilitation program delivered remotely. The verdict, published in BMC Complementary Medicine and Therapies, is nuanced: the supplement did not outperform placebo, but nearly everyone improved, and those who stuck most closely to the program gained the most.

Specialized pro-resolving mediators, often abbreviated as SPMs, are lipid-derived signaling molecules that the body naturally produces to orchestrate the resolution of inflammation. Unlike anti-inflammatory drugs that broadly suppress immune activity, SPMs are thought to actively steer tissues from an inflammatory state back toward homeostasis, promoting clearance of debris and the return of normal cellular function. Because chronic, unresolved inflammation has been repeatedly implicated in the biology of long COVID, researchers hypothesized that boosting pro-resolving pathways with an SPM-enriched marine oil supplement might ease the persistent symptoms that plague patients. The idea is biologically plausible: omega-3 fatty acids such as eicosapentaenoic acid and docosahexaenoic acid serve as precursors for these mediators, and supplementing with concentrated fractions could, in theory, tip the inflammatory balance in a favorable direction.

The trial enrolled 144 adults with a mean age of 50 years, roughly 82 percent of whom were women, all experiencing post-COVID-19 condition lasting more than twelve weeks. The pronounced female predominance mirrors the epidemiology of the condition itself, which disproportionately affects women in midlife. Participants were randomized in a one-to-one ratio to receive either the SPM-enriched marine oil supplement or an identical placebo. Crucially, the study was triple-blind, meaning that participants, clinicians, and outcome assessors were all unaware of group assignment, minimizing bias in both treatment delivery and measurement. Every participant, regardless of supplement allocation, also completed a twelve-week asynchronous telerehabilitation program delivered through the HEFORA digital platform, allowing them to perform prescribed exercises at home on their own schedule.

The researchers chose health-related quality of life, measured with the widely used EQ-5D-5L instrument, as the primary outcome, reflecting the fact that long COVID is fundamentally a condition that degrades daily functioning rather than a single measurable physiological deficit. A battery of secondary outcomes captured the multidimensional nature of the syndrome: fatigue was quantified with the Fatigue Severity Scale, breathlessness with the Modified Medical Research Council dyspnea scale, respiratory muscle strength through maximal inspiratory and expiratory pressures, functional capacity with the six-minute walk test, and limb strength using thirty-second sit-to-stand and arm curl tests. Analyses followed an intention-to-treat approach, meaning every randomized participant was analyzed within their assigned group regardless of adherence, a method that preserves the randomization and gives the most conservative estimate of real-world effect.

After twelve weeks, the headline finding was a null one: there were no statistically significant differences between the supplement and placebo groups on any outcome, with all between-group comparisons yielding p-values above the conventional 0.05 threshold. In plain terms, adding the SPM-enriched supplement to telerehabilitation conferred no measurable advantage over telerehabilitation alone. For a field crowded with unproven remedies marketed to desperate patients, this kind of rigorous negative result carries real scientific value. It signals that, at least in this unselected population of long COVID patients and over a twelve-week window, simply supplying pro-resolving lipid mediators is not sufficient to accelerate recovery beyond what structured exercise and rehabilitation achieve on their own.

Yet the within-group results tell a more encouraging story. Both groups improved substantially across nearly every measure. Participants in the nutritional group walked an average of 37.82 meters farther on the six-minute walk test by the end of the program, a change that reached high statistical significance and that clinicians generally regard as meaningful for daily function. Quality of life scores rose, fatigue severity fell, and both limb strength and respiratory muscle pressures increased significantly. The placebo group showed a strikingly similar pattern of gains, with the sole exception of dyspnea, which did not improve significantly in that arm. The near-identical trajectories of the two groups reinforce the interpretation that the rehabilitation program itself, rather than the supplement, drove the observed recovery.

The trial’s exploratory adherence-stratified analyses added an intriguing wrinkle. When participants were sorted by how faithfully they followed the intervention, those with higher adherence displayed larger improvements than their less compliant counterparts. This pattern is consistent with a dose-response relationship for the rehabilitation component, but it also leaves open the possibility that the supplement might benefit a subset of highly engaged patients. The authors themselves are careful on this point: adherence-stratified analyses are exploratory and vulnerable to confounding, since people who adhere well to supplementation may also adhere better to exercise, sleep recommendations, and other health behaviors. The finding is best read as a hypothesis generator rather than evidence of efficacy.

The study’s design and funding deserve attention when weighing its conclusions. The trial was registered as NCT06063031 in September 2023, approved by the Ethics Committee of Aragón, and conducted with written informed consent under the Declaration of Helsinki. Funding came from the Government of Aragon through an industrial research call in the pharmaceutical sector, with the company SOLUTEX G.C. S.L. as beneficiary and the Aragón Health Research Institute subcontracted to manage the project. One author disclosed participation in the European project where the HEFORA platform was developed. These industry-linked arrangements are disclosed transparently, and the triple-blind, placebo-controlled architecture provides substantial protection against bias, but readers should nonetheless note the commercial interest in the tested product.

What does ARACOV-02 mean for the millions still struggling with long COVID? First, it strengthens the case for rehabilitation as a core intervention. A twelve-week, home-based, asynchronous telerehabilitation program produced measurable gains in walking distance, fatigue, quality of life, and respiratory and limb strength, all without requiring patients to travel to clinics, a significant advantage for a population whose symptoms often make travel exhausting. Telerehabilitation platforms like HEFORA could therefore extend evidence-based care to patients in rural areas or those too debilitated for in-person programs. Second, the trial tempers enthusiasm for SPM supplements as a general remedy, suggesting that unselected supplementation does not reliably outperform placebo in this heterogeneous patient population.

The authors point toward the next logical step: biomarker-guided studies that identify which phenotypes of post-COVID-19 condition, if any, are most likely to respond to pro-resolving nutritional strategies. Long COVID is almost certainly not a single disease but an umbrella term covering several mechanistically distinct subtypes, including those dominated by viral persistence, autoimmunity, dysautonomia, and unresolved inflammation. A supplement targeting inflammatory resolution might help the inflammatory subgroup while leaving others untouched, an effect that would be diluted to invisibility in an unstratified trial of 144 participants. Until such biomarker-driven trials are completed, patients and clinicians should view SPM supplementation for long COVID with measured skepticism, while taking genuine encouragement from the demonstrated power of structured, remotely delivered rehabilitation to restore function and quality of life.

Subject of Research: A randomized controlled trial of specialized pro-resolving mediators and telerehabilitation for post-COVID-19 condition

Article Title: Effects of specialized pro-resolving mediators and telerehabilitation on fatigue, dyspnea, and quality of life in post‑COVID‑19 condition: the ARACOV-02 randomized controlled trial

Article References: Carpallo-Porcar, B., Jiménez-Sánchez, C., Calvo, S., Kolesnyk-Sumskaya, E., Aller-Blanco, A. I., Gómez-Barrera, M., & del Corral Beamonte, E. (2026). Effects of specialized pro-resolving mediators and telerehabilitation on fatigue, dyspnea, and quality of life in post‑COVID‑19 condition: the ARACOV-02 randomized controlled trial. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05630-w

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05630-w

Keywords: post-COVID-19 condition, long COVID, specialized pro-resolving mediators, telerehabilitation, randomized controlled trial, fatigue, dyspnea, quality of life, nutritional supplement, omega-3 fatty acids, functional capacity, respiratory muscle strength